title: [Bone mineral density in idiopathic inflammatory myopathies].
abstract: The study was undertaken to examine the impact of glucocorticoid therapy (GCT) on mineral bone density (MBD) in patients with idiopathic inflammatory myopathies. Double-energy X-ray absorptiometry was used to determine MBD of the vertebral column and proximal femur in 42 females (30 with the preserved menstrual cycle (PMC), 12 in postmenopause (PMP) with polymyositis/dermatomyositis (PM/DM). All the patients received GCT. A random population sample including 106 females aged 20 to 69 years formed a control group. MBD of the neck of the femur was significantly lower in patients from all age groups, in the lumbar vertebral column in young (20-29 years) and old (over 50 years) females than in the controls. The development of osteoporosis (OP) was more frequently observed in PMP females: OP in the lumbar spine was in 16.7 and 66.7% of the PMC and PMP females, respectively; that in the neck of the femur was in 11 and 33%. There was no relationship between MBD and the specific features of GCT, namely the duration, cumulative dose, and the maximum dose. There was a reduction in MBD in patients with PM/DM on GCT in all age groups, more frequently in PMP patients.
authors.forename: O A
authors.initials: OA
authors.lastname: Antelava
authors.forename: A V
authors.initials: AV
authors.lastname: Smirnov
authors.forename: N V
authors.initials: NV
authors.lastname: Demin
authors.forename: A N
authors.initials: AN
authors.lastname: Khitrov
authors.forename: L I
authors.initials: LI
authors.lastname: Benevolenskaia
authors.forename: E L
authors.initials: EL
authors.lastname: Nasonov
mesh_terms: D015502:Absorptiometry, Photon; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects*; D016022:Case-Control Studies; D003882:Dermatomyositis / Q000188:drug therapy; D005260:Female; D005272:Femur Neck / Q000187:drug effects; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008159:Lumbar Vertebrae / Q000187:drug effects; D008875:Middle Aged; D009220:Myositis / Q000188:drug therapy* / Q000378:metabolism; D010024:Osteoporosis / Q000139:chemically induced* / Q000378:metabolism; D017285:Polymyositis / Q000188:drug therapy; D011239:Prednisolone / Q000009:adverse effects
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011239:Prednisolone